Journal article
Radiomics and radiogenomics in ovarian cancer: a literature review.
- Nougaret S IRCM, Montpellier Cancer Research Institute, INSERM, U1194, University of Montpellier, 208 Ave des Apothicaires, 34295, Montpellier, France. stephanienougaret@free.fr.
- McCague C Department of Radiology, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
- Tibermacine H IRCM, Montpellier Cancer Research Institute, INSERM, U1194, University of Montpellier, 208 Ave des Apothicaires, 34295, Montpellier, France.
- Vargas HA Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
- Rizzo S Istituto di Imaging della Svizzera Italiana (IIMSI), Ente Ospedaliero Cantonale (EOC), Via Tesserete 46, 6900, Lugano, CH, Switzerland.
- Sala E Department of Radiology, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
- 2020-11-11
Published in:
- Abdominal radiology (New York). - 2020
English
Ovarian cancer remains one of the most lethal gynecological cancers in the world despite extensive progress in the areas of chemotherapy and surgery. Many studies have postulated that this is because of the profound heterogeneity that underpins response to therapy and prognosis. Standard imaging evaluation using CT or MRI does not take into account this tumoral heterogeneity especially in advanced stages with peritoneal carcinomatosis. As such, newly emergent fields in the assessment of tumor heterogeneity have been proposed using radiomics to evaluate the whole tumor burden heterogeneity as opposed to single biopsy sampling. This review provides an overview of radiomics, radiogenomics, and proteomics and examines the use of these newly emergent fields in assessing tumor heterogeneity and its implications in ovarian cancer.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1007/s00261-020-02820-z
- PMID 33174120
- Persistent URL
- https://sonar.ch/global/documents/210325
Statistics
Document views: 60
File downloads: